CFL1 and fragile X syndrome: We also show that LIMK inhibitors areeffective in reducing phospho-cofilin levels in iPSC neurons derivedfrom FXS patients, demonstrating 85 to be a potentialtherapeutic candidate for FXS that could have broad application toneurological disorders or cancers caused by LIMK1/2 overactivationand actin instability.